newsfilter
← Latest News
Earnings Call Transcripts·

Auna 3Q26 Conference Call - AUNA SA

Good morning, and welcome to AUNA's third quarter 2026 earnings conference call. My name is Alexandra, and I will be the operator for today's call. At this time, all participants are in a listen-only mode, and please note that this call is being recorded. There will be an opportunity for you to ask questions at the end of today's presentation. Now, I would like to turn the call over to Ana Maria Mora, Head of Investor Relations. Ma'am, please go ahead. Thank you, Operator. Hello, everyone, and welcome to AUNA's conference call to review our third quarter results. Please note that there is a webcast presentation to accompany the discussion during this call. If you need a copy of the presentation, please go to our Investor Relations website or contact AUNAS' Investor Religions team. Please note that when we discuss variances, we will be doing so on a year-over-year basis and in FX-neutral or local currency terms with regard to Mexico and Colombia, unless we know otherwise. Let's move to slide two. In addition to reporting unedited financial results in accordance with international financial reporting standards, we Will discuss certain non-IFRS financial measures and operating metrics, including foreign exchange neutral calculations. Investors should carefully read the definitions of these measures, the metrics and reconciliations included in our earnings press release published yesterday after market close, to ensure that they understand them. Non-IFRS financial measures and operating metrics should not be considered in isolation as a substitute for or superior to IFRS financial measures and are provided as supplemental information only. Before we begin our remarks, please also note that certain statements made during the course of today's discussion may constitute forward-looking statements which are based on management's current expectations and beliefs and which are subject to a number of risks and uncertainties that could cause actual results to materially differ, including factors that may be beyond the company's control. These include, but are not limited to, a revenue-adjusted WDA and capital expenditure guidance, our target leverage ratio, the results of the key initiatives we are implementing in Mexico, Colombia, and Peru, the timeline for the construction and commencement of operations at Centro Ambulatorio Treca, the expected capacity and market of Centro Ambulatorio Treca once built, our ability to recover any loss under the oncology risk sharing contract in Colombia, the execution of our strategic plan, our planned investments, our expected revenue growth and adjusted EVDA growth, the expected impact of regulatory price caps in Colombia and the creation of further growth and sustainable value for all stakeholders. For a description of risks that may impact our forward-looking statements, please refer to our Form 20F filing with the U.S. Securities and Exchange Commission and our earnings press release. Slide three, please. On today's call, we have Suso Zamora, our Executive Chairman and President, Giselle Remy, our Chief Financial Officer and Executive Vice President, and Lorenzo Mazard, our executive vice president of strategy and equity capital markets. They will discuss AUNA's consolidated and segment financial and operating results for the quarter, as well as provide an update on our various strategic growth initiatives. after that we will open the call for your questions suso please go ahead thank you annie let's begin with slide four please we maintained our growth momentum across sauna's regional platform in the third quarter delivering top-line growth of 10 percent on fx neutral basis particularly encouraging was the acceleration of growth in mexico with improving profitability and its first quarter of year-over-year adjusted EBITDA growth in 2026, and the fourth consecutive quarter of growth. In Colombia, profitability was pressured by significant medical costs under specific oncology risk-sharing contract and drug pricing caps. Importantly, the underlying business continued to demonstrate strong momentum, delivering a third consecutive quarter of robust revenue growth supported by increased high complexity care. We took decisive action to address the situation and will discuss this particular contract in more detail in today's presentation. Third quarter profitability was also impacted by penalties related to the reconciliation of prior years receivables in Peru. The underlying strength and growth potential of our Peru segment remain intact and we continue to see significant opportunities from our strategic focus on high complexity care and other growth initiatives in this market we sustained strong cash generation driven by disciplined working capital management and improved cash conversion directly supporting our ongoing deleveraging efforts let's move to slide five our third consecutive quarter of strong revenue growth and the 95 year-over-year increase in year-to-date free cash flow demonstrate the continued strength of our platform's fundamentals. This robust cash generation supported the sequential improvement in our leverage ratio to 3.5 times, bringing us closer to our medium-term target of three times. This underlying strength is also reflected in the operating metrics at the bottom of this slide. Total capacity utilization in our healthcare services network increased year-over-year to 68% on a year-to-date basis, reflecting continued improvement in utilization across our platform. In Mexico, total capacity utilization increased two percentage points year-ever-year during the quarter. In Peru, total plan memberships continued to grow, and OncoSalud's oncology MLR stood at 50.7%. These trends, together with the quarterly operating metrics we published last month, reinforced our confidence in our integrated healthcare model and the AUNA way. We remain confident in the medium- to long-term potential of our increasingly scaled and integrated regional platform. Let's move to slide seven for a closer look at our performance in Mexico. Driving the acceleration of Mexico's top line and the recovery in profitability were increases in surgery volumes, up 12% year-over-year, as well as chemotherapy and radiotherapy sessions, which increased 34%. These trends demonstrate that the owner way and our strategy continue to gain traction in Mexico, a key market for owner's long-term growth. While our insurance business in Mexico navigated industry-wide headwinds from the new VAT deductibility regulations, the strength and volume growth of our Monterey healthcare network more than offset those impacts, allowing Mexico's segment adjusted EBITDA to return to year-over-year growth. Despite the VAT's impact on Mexico's insurance market, we remain excited about the opportunities in the B2B segment through AUNA Seguros, building on our established position and effective sales channels in dental and vision insurance. Moreover, our thesis on the long-term potential of oncology insurance in Mexico has not changed. We see significant opportunities to develop this product, further strengthen AUNA's vertical integration, and expand access to our value-based care model in this market. Slide eight, please. Driving Peru's top-line growth was a 21% increase in surgery volumes, along with an 18% increase in chemotherapy and radiotherapy sessions, as we further prioritize high complexity procedures across our healthcare network. Another driver was our greater focus on higher retention B2B accounts through OncoSalud's multi-channel access model. By way of example, we expect to onboard approximately 4,000 additional PAN members in the fourth quarter following the signing of two new corporate agreements. The onboarding of new B2b accounts, which have yet to reach normalized utilization levels, together with higher pharmacy and clinical payroll expenses associated with increased hospitalization and emergency volumes, weighed on Peru's profitability during the quarter. Results were also affected by the penalties related to the reconciliation of prior year's receivables. These factors contributed to a 6% decline in consolidated Peru adjusted EBITDA. Excluding the billing related penalties, adjusted EBIDDA would have remained broadly stable year over year. Let's turn to slide nine. The underlying fundamentals of our business in Colombia remain strong, as announced last quarter. We expanded our ICU and hospitalization capacity at IMAT, OncoMedica, and Monteria to support growing demand for high-complexity care. Additionally, we further diversified our payer base, increasing revenues from private payers while further reducing our exposure to government-intervened payers. While we delivered a 12% increase in Colombia's revenues in local currency, segment-adjusted EBITDA declined 30%, primarily reflecting two factors. First, extraordinary adverse medical costs under a specific oncology risk-sharing contract representing approximately 4% of Colombia's revenue. revenues. This contract covered approximately 500,000 lives and experienced a significantly higher incidence of advanced stage cancer cases than anticipated, resulting in treatment costs that significantly exceeded contractual assumptions. We have since terminated this contract to limit further exposure and have engaged legal counsel to review all recovery options under the contract. Second, regulatory price caps enacted since mid-August impacted the third quarter and will continue to carry an impact in the fourth quarter as we implement the operational changes to contain this cost increase. Inflationary pressures such as high personnel costs reflecting mandatory wage increases in the statutory reduction in the standard work we already discussed in previous quarters continued to weigh on our Colombian operations to mitigate the impact of these pressures we continue to focus on actively managing our revenue mix and payer portfolio as well as initiatives to improve operating efficiency across our colombian network with the objective of recovering our structural margins while these headwinds have affected our near-term results our priority remains strengthening contract economics and building on the growth opportunities across our Colombian healthcare network. I'll now turn the call over to Giselle who will review our results in more detail. Thanks Suso and good morning everyone. Let's now turn to slide 11 please. Our strategic focus on delivering more high complexity services and value-based care continued driving revenue growth across our regional platform during the third quarter. In Mexico, the 12% increase in surgery volumes and 34% increase in oncology services drove a 2.9 percentage point increase in total capacity utilization, which rose to 41%. In Peru, where AUNA is vertically integrated, surgeries grew an impressive 21%, while average monthly revenue per membership plan increased 5%, reflecting our successful strategy to onboard high-quality corporate B2B accounts, retain more profitable members, and maintain disciplined pricing across our plans. In Colombia, we continued capturing more growth in the private market, with revenues from private payers increasing 22% in the quarter. Other growth drivers were the reactivation of ICU beds and the addition of hospitalization beds in Monteria. Let's now move on to adjusted EBITDA on slide 12. As you can see in the bridge on this slide, our consolidated EBITda reflects three distinct quantifiable drivers. First, on the positive side, Mexico achieved 5% year-on-year growth in adjusted EBITDA, demonstrating the operating leverage we are beginning to capture in that market. Notably, the Monterrey Healthcare Network's adjusted EBIDDA increased 10% year on year, helping to mitigate soft results at AUNA Seguros due to the sector-wide change in the deductibility of VAT. However, this underlying growth was temporarily offset by two extraordinary items in Colombia and Peru. In Peru, our results absorbed 18 million soles in revenue adjustments, primarily related to the prior year's billing matters. Excluding the net impact of these revenue adjustments EBITDA would have been broadly stable year over year. As we've previously communicated, we have seen continued improvements in our internal billing cycle, helping to protect us from these types of impacts in future revenue billings that we generate. As such, we should be absorbing the majority of these impacts in the coming quarters, paving the way for Peru's EBITDA margins to recover towards their historical levels in the low 20s. In Colombia, our results were impacted by the previously mentioned specific oncology risk-sharing contract, where treatment costs significantly exceeded contractual assumptions, as well as new regulatory price caps on high-cost oncology medicines. We have successfully terminated this unprofitable contract, which represented approximately 4% of Colombia's revenue, effectively eliminating this near-term headwind. Additionally, it is important to note that the price caps only had a partial effect in the third quarter, as they were implemented halfway through the period. Let's now move to slide 13, please. Our adjusted net income decreased versus the third-quarter of 2025, driven by accounting effects rather than operational cash performance. Specifically, the decrease reflects the absence of a 40 million soles non-cash FX gain that we recorded in the same period last year. This is in line with what we have noted in previous quarters regarding the fact that following our most recent refinancing exercise in the fourth quarter 2025, we reset the levels on our FX hedges. Therefore, future FX variances should be very limited and should only occur when the U.S. dollar SOL moves outside the 3.4 to 3.8 range. Our underlying net finance costs, when you strip out FX impacts as well as the non-cash impact of the future purchase obligation of IMAT Oncomerica, actually improved year over year. Our current blended interest rate, including hedges and a majority of local currency funding, is at 10.38% year-to-date. The other significant and positive delta in the quarter was a 20 million soles decrease in income tax expenses. Let's turn to cash flow on slide 14, please. We continue to effectively increase cash conversion through improved collections, as well as a reduced net tax payment across our platform. Year-to-date, net operating cash flow increased 62 percent to 713 million soles, while free cash flow surged 95 percent to 626 million soles. This strong performance was driven by disciplined working capital management, specifically improved collections and lower accounts receivable days in Peru and Mexico, as well as stable collections in Colombia, alongside lower tax payments. Over the nine-month period, our cash conversion cycle improved from negative nine days in 2025 to negative 15 days, allowing us to continue generating cash through active working capital management. Year-to-date, our cash position increased 83% to 614 million soles, keeping us on track to reach our medium-term leverage target of three times. Lastly, at 3% of revenue, our capex remained comfortably below our 4% full-year guidance. Let's now move to our debt profile on slide 15. In addition to the slight improvement in net debt leverage resulting from Aona's increasing cash flow, it's important to note that our gross debt decreased by 7 million soles on an FX-neutral basis, an improvement masked by the depreciation of the sol against the U.S. dollar, which resulted in an increase of 90 million soales since year-end 2025. At the end of the third quarter, we had $194 million in credit lines, of which just over $134 million was still available for use. It's also important to note that 54% of our debt is in local currencies, while 85% of the balance in the U.S. dollar denominated debt is hedged against the Peruvian soy. In addition, 75% of our floating interest Mexican debt is also hedged. Finally, of the 481 million soles of gross debt coming due in the next year, 216 million sores corresponds to revolving working capital debt, which is renewed at maturity, and which is amply covered by the 194 million U.S. dollars in credit lines already mentioned. Additionally, 165 million soles corresponds to the short-term maturities on our 2030 term loan, and which is also amply covered by the 614 million sores in cash balance at the close of the third quarter. The remainder corresponds to other short-term maturities of long-term borrowings, as well as the accumulated interest on our outstanding 2029 and 2032 bonds. That concludes my review. I'll now hand the call back to Suso, who has a few closing remarks, before we open the call for questions. Thanks, Giselle. Consistent with the outlook communicated in October and in yesterday's earnings release, we continue to expect full-year 2026 revenue growth within our guidance range of 10% to 14% on an FX-neutral basis. Adjusted EBITDA is expected to remain broadly stable or slightly down year-over-year. This principally reflects the extraordinary medical costs associated with the terminated oncology contract in Colombia, as well as the impact of regulatory price caps on certain high-cost oncology medications. Our capital expenditures guidance also remains unchanged at approximately 4% of consolidated revenues. In Peru, where our integrated model has been operating at scale, we expect to capture the significant growth opportunities that remain in this market, with a focus on expanding high-complexity services beyond oncology, including neurosurgery, traumatology and orthopedics, as well as cardiovascular surgery. We expect profitability to improve as the onboarding of new B2B accounts normalizes. Mexico is now well positioned for sustained growth and improving profitability, supported by improved payer classifications, continued physician onboarding, the expansion of our oncology franchise, and growing surgical volumes. Mexico has also maintained its growth momentum so far in the fourth quarter. While we remain cautious on Colombia in the near term, given the regulatory and operating cost pressure discussed earlier, the market remains an integral part of our regional platform. We expect Colombia to gradually recover and once again become an important contributor to profitable growth, supported by the continued expansion of high-complexity care in Monteria and our PGP arrangements. Finally, strong free cash flow generation enables us to further strengthen our balance sheet and make progress toward our medium-term leverage target of three times. Before we open the call for questions, I want to emphasize that, as we address these near-term headwinds, we remain confident in the long-term potential of our regional platform, our integrated care model, and our market-specific strategies. Our focus remains on accelerating growth in Mexico, restoring profitability in Colombia, improving earnings quality and operating efficiency in Peru, and translating our commercial momentum to stronger cash generation and growing sustainable returns for our shareholders. Operator, please open the call for questions. At this time, we will open the floor for your questions. If you have dialed in and would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star one again. If you are listening via the webcast link, please submit your questions online by using the Q&A function in the bottom right corner of the webcasting. Please hold while we compile the Q and A roster. A reminder, if you would like to ask a question, please press star 1 on your telephone keypad. Our first question comes from the line of Mauricio Cepeda with Morgan Stanley. Mauricio, your line is now open and live. Please proceed with your questions. Hi, Susu, Giselle. Thank you. Thank you for the opportunity here. We have two questions. The first one regarding Colombia. So the fact that you had this kind of bad experience in this particular contract, So are other contracts also subject to a pressure like this, and how does this would change your appetite from now on to expand the risk-sharing partnerships, or how would it change the type of protections you require in the contracts? So this will be our first question. And the second one about Mexico, now that the capacity utilization is improving, how do you see as a realistic longer-term utilization target for the existing hospital base, and what could be an EBITDA margin if you consider the operating leverage effect under your current payer mix? Thank you. Great, thank you very much Mauricio, it's always good to hear your questions as one of the first ones in our quality results review, we appreciate that. In Colombia, I would say that we do not think what has occurred with one of our PGP contracts, a newer contract, has any contagion effect or any replicability in the rest of our PGPs and PIPs contracts. So we don't think it's a sector issue, it's very specific. off one contract you know um situation and um we think um we've taken action on it no i am with respect to the broader question um yeah as we see colombia um of course colombian offers us offers us a huge healthcare market given its universal healthcare sector um but for us in particular you know it gives us an opportunity to take on a larger market share of high capacity pockets of value that's very important but we are and and this is um something that um we're working on aggressively but of course it has come with too much structural risk. And this we will resolve with urgency. I would say that those are my points on Colombia. I don't know, Gisele, if you want to chime in with anything else on Colombia, then I can go into Mexico. Yeah, and thank you, Mauricio, for the question. Very much in line with what Suso has already commented, the adverse effect on the risk-sharing contract in oncology in Colombia was very specific to the high incidence of execution of costs on this contract. And given that we have also received some questions as to quantifying the effects, I wanted to complement that of the $4 million drop that we saw in Colombia's EBITDA versus the third quarter of last year, we estimate that approximately 70% of that was due specifically to this oncology risk-sharing contract, which has already been terminated, and the remaining 30% is due to the price caps on high-cost medicines in Colombia previously mentioned. So we're going to have a continuing effect of those price caps into the fourth quarter for the three-month period in the fourth corridor. It was only 30% in the third quarter, given that it was halfway through, as I mentioned, but we will have that impact in the three months of the fourth quarter. Okay. Okay. Thank you. And sorry, Suso, you were going to move on to the Mexico question? Yeah. Sorry. I forgot to unmute myself, so I was giving a very long-winded, but I'll try to summarize that. Thank you, Mauricio. I wanted to thank you, Jason, for that additional comment on Colombia. So on Mexico, as you can see, momentum is continuing to build up. Of course, this quarter, we marked the first with year over year growth. No, and it's really important to contextualize this in a very difficult year in the insurance market in Mexico, where the VAT has diminished in the number of policyholders in Mexico. It's an event that hasn't occurred in 15 years. So it's very important, and we're growing. So notwithstanding that the market has shrunk like a million policies, we are growing. And I see that we're going on increased intimacy with payers, recognition that we can contain costs, and grow volume, especially in higher complexity. So, yeah, and you can see that, of course, with our contract with East de Leon, which, again, what's highlighted is our confidence and our capacity to deliver great service at the appropriate cost. You can seethat in the growth in chemotherapy, in radiotherapy, in surgeries. You cansee all those growing. And we are acting clearly on the levers so that margins continue to recover as utilization increases. You specifically asked about utilization. We see utilization growth in our chemotherapy treatment centers, in our, of course, the new machine that we have now in the radiotherapy center, and beds as well, but slowly, but slow. I think that we can add two or three percentage points a year and remain with increasing margin growth. And that's very important. So it's not about just volume. It's about how you grow and you maintain good margins. So I think our thesis in Mexico has not changed. But the underlying market opportunity is really interesting. It continues to be interesting, notwithstanding this huge sector change with the VAT. So I think that would be my response on Mexico. In terms of EBITDA margins, I can just tell you, Mauricio, that given the inflection point that you've seen in volumes, and given that this is a scale business, you will see us recover the EBITDA margins that we've had in the past and that can sustain a growing business, a growing and much more profitable business in Mexico. We're excited about Mexico. And Gisele, you want to add something on that? Yes, so I think the margin recovery that we're seeing in Mexico the last few quarters is particularly promising, not only in the market context, but also when we consider that specifically behind that 26% EBITDA margin, you have the healthcare network in Monterrey at a 28% EBITTA margin at 41% occupancy levels. So I think as we continue to see that ramp up in occupancy, we will continue to see um positive impacts on on that ebitda margin um and and we're very optimistic about the evolution of that volume growth in in the coming quarters yeah and i would add that um i would ask that um 80 percent of our payer relationships have um confirmed the tiers in which we currently operate which is a larger populations that um that are covered by insurance So that's very important. We have a very stable base of payers, of course, payer patient volumes. And I would also say that we're growing out of pocket nicely. Not long ago, it was around 6% of revenues. We're close to 9%. And we envision maybe as much as doubling that. So, and Mexico has one of the highest out-of-pocket payers, I mean, families and individuals in the world. So, we see that as a great opportunity to also have an impact in capacity utilization. Thank you, Mauricio. No, thank you. There are no more questions from the phone lines. So I will now turn the call over to Ana Maria Mora from AUNA who will proceed with questions from the webcast platform. Thank you, Operator. Good morning, everyone. Thanks for joining. The first question comes from Alonso Alcorta, and it is, what are the plans for the remnant of the UNAS 29 bonds? Thank you. Thank you for the question. And to briefly answer. The remnant of the 2029 bonds is approximately $100 million outstanding, which come due in three years towards the end of 2029. These bonds are callable at the end of this year at 105%. So what I would comment is that AUNA is constantly reviewing market opportunities to have the most efficient capital structure. We still have more than three years to tackle that maturity, but we are obviously constantly evaluating the best alternatives to refinance that amount. Thank you, Jason. Give me one second. The next question comes from Omar Avellaneda. And the question is, is there any negative impact expected on EBITDA margin for Q4-26 due to the headwinds experienced in 3Q-26? I can tackle that question to start off. So if you have anything more to comment. Yeah. So of the of the headwinds that we've commented in in the third quarter, as we've previously mentioned and also commented in our updated guidance, we will continue to see impacts into the fourth quarter related to the billing matters in Peru, as well as the price caps in in Colombia. We will continue to see recovery of the Mexico business in the fourth quarter, and we will continue to see EBITDA growth into the fourth corner of Mexico's EBITTA. And I think it's also important to note that in the case of Peru, as we've previously mentioned, operating KPIs and operating trends continue very, very positive. Cash flow generation has improved significantly as we have been able to reduce the internal billing cycle and the cash flow conversion off the back of improved collections. So we will have these two margin pressures related to the billing matters in Peru and the price caps in Colombia. However, operating trends into the fourth quarter as well as going into next year, continue positive. And that is what will take us to margin recovery in the coming quarters. Yeah. And I would add, G, say that more directionally, I mean, 2026 has been, and this quarter in particular, has been about extraordinary, unexpected impacts to our results. And while we're working, of course, on the quantitative results for the rest of the year and in the coming year, it's important that you also take note that we'reworking on the qualitative nature of predictability. We cannot be about these exogenous events. We need to make sure that, first of all, we have full control of what we're doing, the services that we're delivering. And we have a great opportunity, including in Colombia, that has always a quarterly headline, I would say. Not a surprise, but a headline. So I think we're working with great decision and producing a deliberate plan to address the qualitative nature of our results. That is predictability. We want to make sure that the investor community sees us delivering without surprises. Now, these quarters have been, I call them dirty quarters, with a lot of extraordinary events. We have it on our agenda. We're going to tackle that. Thank you. Thank you, Suso. Okay, the next question is about OncoSalud. What are the headwinds you're experiencing at OncoSalud? It is growing lower than last year. I think in general, in Peru, there are various factors that are producing some net reductions our population base but um i see that in in in general um uncle salute is seen as one product but actually um it is made up of many different products with the different price points and also now we're offering different coverages of other high complexity and limited um general healthcare um coverage now and um i think um it's not a question about headwinds it's a question about how to address a market that that market that um trusts the uncle salute brand you know in in in a segment that um has a limited amount of disposable income to address health care um the healthcare expense burden of a family you know i think um it's not that anything in particular has to be done we need to continue to do what we've done for decades now to make sure that we have an affordable product you know that covers well the ailments especially prevention early detection you know and produces of course these high survivor rates at an accessible price i don't think there's um there's any headwinds in particular but um small um commercial you know um actions that are required to continue to grow our our covered population Thank you, Suso. And just to continue on the topic of Peru, there's another question from Saikat, and he's asking, you know, with hospitals in Peru running at 90% utilization, how do you see volume growth potential from here? Well, again, we're so focused on high complexity that sometimes the measurement of beds is not the most appropriate, no? And as you might have seen from what we have reported in the past, we are building a site in the south of Lima that addresses capacity utilization. And more importantly, we're doing more and more in high-complexity outpatient services. And I think that's a key strategic direction of how we build capacity. And I Think some of the research analysts have always published our asset light strategy. so we don't need to build these huge hospitals we have everywhere we can actually just margin and build as a light facilities that that can deliver services for hundreds of patients and family members a day without huge investments and that's that you will see us pushing that lever aggressively you know in particularly in peru and colombia Thank you, Suso. The next question- I'm sorry, Annie, I'm, I just want to make sure that we are comfortable, I forgot to respond to this part, we're comfortable at 90% capacity utilization. We run our hospitals at those levels, and above that, it triggers an immediate need to act on the asset-light expansion, as I indicated before. Thank you. I just wanted to make that point. Thank you, Suso. To continue on the topic of Peru, there's a question, a couple of questions from Temo Tarrago. He's asking, when will the Peruvian billing issues wrap up? And then about Mexico, I understand that VAT issues in Mexico will normalize because they affect everyone. Is that correct? Will there be diminished overall demand because of that? And finally, any news on the Sojit's MOU? Okay. Let me tackle the second one so that I can pass the mic to you, Adise. So on VAT in Mexico, it should be read in a different light. Yes, it does affect everybody. It does affect anybody, but it actually gives a benefit to those of us that have a cost point for insurance payers that is most attractive and that's why you see us grow yes it does affect everybody but we have a price point that's very attractive to insurance companies and we're growing i think we continue to do that with the pressures of you know the insurance companies and the first question was um on peru and gc on um and revenue reconciliation And the third question was on SOGIES, I think, right? Correct. Just quickly to tackle the Peru question on when we expect the billing issues in Peru to normalize. As I mentioned earlier, we have had very material improvements in the internal billing cycle. And as we've mentioned in previous quarters, we continue to negotiate reconciliations from previous periods, which is why we continue to have these effects being reflected in the coming quarters. We do expect to be able to reflect the effects related to previous periods within the next coming quarters and then be able to normalize those effects towards the second half of 2027. And then on SOGIT, we're making good progress in the relationship with SOGIS. We think we should have something at the beginning of the year perhaps to announce. We're excited about partnering with them and they have such a credible healthcare footprint elsewhere. But we're still early to talk much about it. But we are we're excited about the adventure. Okay, thank you. And then to continue on, well, we diverted from Peru, but I'd like to address Torre Treca. Umara Villaneda asked, Can you explain the next steps regarding the Torre Trecca project? Right. So the good news is that the Torre Trecca Project, the Centro Ambulatorio Torre Trecca is on schedule. I think it was a week ago or two weeks ago that we actually dispersed the first payment for construction. So and we had the President, we had President Fujimori, visiting the site less than two weeks ago as well, with the head of the Social Security in Peru. So I think we're on time and we don't see any surprises in the near future on that project. We're very excited. The government is very excited, I think, we can make a huge difference as we have for other populations that we serve um but it's a it's it's a um it's a very important project not because of the size of the project itself because it will prove auna's capabilities in the b2g b2 government sector which of course you know in mexico and peru in particular is a high multiple five six times of the private sector market So we're really excited about this and where this can take us in B2G and PPP projects in the region. Thank you very much for that question. Thank you, Suso. And as we're getting to the final questions, there is a question about Mexico, and then we'll touch upon the El Nino. So about Mexico, this one's from Giselle. Could you give further color on how long did the 16% revenue increase for the East Telegon B2B agreement at OCA has impacted 3Q? And what would be a Mexico excluding the aforementioned related revenue growth? okay yeah thank you um as we've mentioned in in previous quarters one of the drivers for um volume and margin recovery in 2026 have been related to the renewal of the east along contract towards the end of last year beginning of this year um at better conditions um so obviously that has also had the effect of us um taking in a higher amount of volume versus the comparable period of last year. And we will continue to see our B2G segment, as Suso has mentioned, in the case of Mexico and specifically Monterrey, having a positive impact on our revenue mix. And it's a segment that we are very interested in growing also in the coming years. Thank you, Gisele. And finally, the last question in the queue is about the phenomenon del niño potential and the impact. If you could discuss how we're going to support the infrastructure continuity and the medicine supply. Thank you. Yes, thank you, Annie. And as we also mentioned in our investor day, you know, the market has a forecast for a strong to extremely strong El Nino for the end of this year, beginning of next year, and weather can be highly unpredictable. So as a result, we've activated a plan that is dedicated to driving forward different actions in order to make sure that we have operational continuity and that we ensure the safety of our patients and our staff. In line with that, we are reinforcing infrastructures. We're ensuring critical supply for different medications and other kinds of supplies. And we're making sure that we have backup supplies for fuel, water, electricity, and our own generators, both backup generators, making sure that we pre-organized flows for patients back and forth between where we need. And also in continuing to make sure that we have guaranteed flows between northern Peru and Lima and between Arequipa and Lima. So we're doing this not only for Piura, Chiclayo, and Trujillo, where probably most of the impact will happen, but also in Arequepa and Limas, so across our entire Peru network. We're doing the same thing for the rest of the country, but we're also doing the this as efficiently as possible, but again, making sure that we cover and make sure that our patients will be well taken care of and also ensuring the safety of our staff. Okay. Thank you, Giselle. I think with that, we have reached the end of our question queue today. So thank you all for your time and participation. And so let me hand it back to you for some final thoughts thank you annie um um before before my final thoughts i was just wanted to add that um we are um as prepared as one can be for nino better prepared than any at any moment in the last decades and we really had ninos and we know what needs to be done and um and we built a lot of cushions to make sure that um our population our populations and our clinical staff you know is um well protected for in your events though um i would like to also highlight i'm not sure this is appropriate for the call we had a very important i would say blessed visit from the pope these couple days in peru you know and um and we had the fortune you know to make sure that if anything occurred to him you know he would be um safe and healthy on the side by owner so we covered his um his visits um with the una staff and the owner ambulances um and i want to say that because that shows um that should show the investment community the capabilities we have you know to sustain you know a a service offering that that is unique that is unique and Nino's unique the visit of the Pope is unique you know there were some masses that had two million people and I think that that should give them the investor community another indicator of how we operate now now in terms of my closing remarks I want I want to be very clear it's been a tough quarter it's been a very tough quarter Colombia is of course concerning but we're on it and I want to make very clear we're we have a great team led by right yet hard no that gives me comfort no we will turn the page on the current challenges and Mexico and Peru are on the right track and gaining momentum so we're very enthused about that we want to thank you for the support thank you very much thank you so much for your attention and with that I would like to close the session thank you this concludes today's conference call you may now disconnect

Company
AUNA SA
Keywords
AUNA SA